Inicio › Mieloma múltiple › Arizona
Ensayos clínicos de Mieloma múltiple en Arizona
28 estudios sobre Mieloma múltiple buscan participantes en Arizona.
Ciudades en Arizona
Texto oficial del estudio (inglés)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- City of Hope Phoenix, Goodyear
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07589634Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic in Arizona, Scottsdale
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06630104A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gilbert
- Research Site, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic 1, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Phoenix, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07258511A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Banner MD Anderson Cancer Center, Gilbert
- University of Arizona Cancer Center, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05201781A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Mayo Clinic Hospital Scottsdale /ID# 278349, Scottsdale
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Phoenix, Phoenix
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Hospital in Arizona, Phoenix
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Banner MD Anderson Cancer Center, Gilbert
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona, Phoenix
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT06375044A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Bullhead City
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Cancer Center at Saint Joseph's, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Phoenix
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Gilbert
- Research Site, Phoenix
- Research Site, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Banner MD Anderson Cancer Center, Gilbert
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Arizona, Phoenix
- HonorHealth, Scottsdale
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Arizona - Phoenix, Phoenix
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 jul 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona /ID# 251405, Phoenix
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Cancer Center at Saint Joseph's, Phoenix
ReclutandoFase 3
Todas las edades · Todos los sexos · Actualizado el 10 jun 2026 · NCT05561387A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Arizona, Scottsdale
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT03017820Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Banner University Medical Center Tucson, University of Arizona, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Banner MD Anderson, Gilbert
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT06433947A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Arizona Oncology Associates, Tucson
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT05972135A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- CTCA at Western Regional Medical Center, Goodyear
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 feb 2026 · NCT07225738De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.